UBS Group
RNAM

UBS Group’s Avidity Biosciences RNAM Stock Holding History

UBS Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,300
Closed -$1.39M – 11065
2025
Q4 		$1.39M Buy
+19,300
New +$1.25M ﹤0.01% 5290

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

UBS Group's RNAM Position: Q1 2026 in Review

UBS Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,356,812 shares — an estimated $170M sold.

UBS Group first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $170M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • UBS Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 2,356,812 Avidity Biosciences shares in Q1 2026, an estimated $170M.
  • UBS Group first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
  • UBS Group's Avidity Biosciences position peaked at $170M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.